Pharmaceutical Industry

Eli Lilly has acquired rights to Insilico Medicine’s AI-discovered drug pipeline in a $2.75 billion deal. This significant partnership highlights AI’s growing role in drug discovery. The agreement includes an upfront payment and future royalties, reflecting the innovative nature of the collaboration. Insilico, a leader in AI-driven drug discovery, has numerous candidates in clinical trials. This deal leverages Lilly’s expertise with Insilico’s AI platform, aiming to accelerate the development of new therapies and reinforce Lilly’s expansion into the Chinese market.

The latest episode of T. Rowe Price’s “The Angle” podcast features a discussion between Eric Veiel and Eli Lilly CEO Dave Ricks on chronic disease management, leadership, and global healthcare challenges. Ricks provides insights into healthcare’s future, particularly regarding innovations in areas like diabetes, cancer, Alzheimer’s, and weight loss drugs. The podcast, part of a C-suite series, aims to offer dynamic perspectives on market trends and connects macroeconomic forces with corporate strategy. “The Angle” is one of two podcasts by T. Rowe Price, which manages $1.79 trillion in assets.

Next week marks a busy earnings season with over 150 S&P 500 companies reporting, especially tech giants like Alphabet, Amazon, Apple, Meta, and Microsoft. Key companies to watch include Corning (strength in optical communication), Boeing (737 Max production ramp-up), Starbucks (turnaround strategy progress), Bristol Myers Squibb (drug trial updates), Eli Lilly (GLP-1 drug viability), Linde (stability). Amazon needs to show AWS revenue acceleration, while Apple’s iPhone demand and services growth are in focus.